Small Molecule Clinical Trials — Our Core Strength
Genelife Clinical Research stands as a leading CRO in India in the domain of small molecule clinical trials, with over 16 years of experience and the successful completion of more than 55 clinical trials. Small molecule pharmaceutical companies — from industry giants to dynamic start-ups — rely on our unparalleled expertise in Phase I–IV studies.
Therapeutic Areas of Expertise
Oncology & Hematology
Solid tumors and hematological malignancies — Phase I dose-escalation through Phase III pivotal studies.
Cardiovascular & Metabolic
Hypertension, heart failure, dyslipidemia, diabetes, and metabolic syndrome clinical trials.
Central Nervous System
Epilepsy, depression, anxiety, Alzheimer's, Parkinson's disease and other CNS disorders.
Dermatology
Psoriasis, eczema, acne, and other inflammatory skin disease clinical trials.
Gastroenterology
IBD, GERD, hepatic conditions, and gastrointestinal motility disorder studies.
Ophthalmology
Glaucoma, macular degeneration, retinal disorders, and other ocular conditions.
Infectious Diseases
Antibacterial, antiviral, antifungal, and antiparasitic compound clinical development.
Respiratory Medicine
Asthma, COPD, pulmonary hypertension, and respiratory condition clinical trials.
Rare Diseases
Orphan drug development and rare disease clinical trials with specialized patient recruitment.
Phase I–IV Approach for Small Molecules
- Phase I: First-in-human studies, dose escalation, PK/PD profiling in dedicated early phase units
- Phase II: Proof of concept, dose-finding studies with optimal site selection and patient recruitment
- Phase III: Pivotal multi-centre studies with robust data management and regulatory-ready deliverables
- Phase IV: Post-marketing surveillance, real world evidence, and comparative effectiveness research
Genelife Clinical Research is a trusted partner dedicated to helping small molecule pharmaceutical companies navigate the full complexity of drug development — from first-in-human through regulatory approval — with quality, transparency, and efficiency.